Literature DB >> 2844447

A bromocriptine-responsive corticotroph adenoma secreting alpha-MSH in a patient with Cushing's disease.

A C Hale1, P J Coates, I Doniach, T A Howlett, A Grossman, L H Rees, G M Besser.   

Abstract

Clinical and in-vitro investigations have been performed on a corticotroph adenoma removed from a patient suffering from Cushing's disease. Prior to surgery, the patient's Cushing's disease had been successfully controlled, clinically and biochemically, by long term administration of bromocriptine. After selective adenomectomy, tumour tissue was investigated by a perfused isolated cell column technique. It was shown that the tumour cells secreted immunoreactive- (IR)- ACTH and IR-alpha-MSH and that the release of both peptides was promptly suppressed by dopamine. Chromatographic analysis of the secreted IR-alpha-MSH revealed a high proportion of acetylated alpha-MSH; smaller amounts of desacetyl alpha-MSH and diacetyl alpha-MSH were present. The relevance of these findings to the proposal that certain corticotroph adenomas are derived from the intermediate lobe of the pituitary is discussed. It is concluded that there is little direct evidence for involvement of the residual zona intermedia of the adult human pituitary in the development of Cushing's disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2844447     DOI: 10.1111/j.1365-2265.1988.tb03658.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Dopamine D2 receptor gene expression in human adenohypophysial adenomas.

Authors:  L Stefaneanu; K Kovacs; E Horvath; M Buchfelder; R Fahlbusch; L Lancranjan
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

Review 2.  Characterization of persistent and recurrent Cushing's disease.

Authors:  Nina K Sundaram; Alessia Carluccio; Eliza B Geer
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

Review 3.  Pituitary-directed medical therapy in Cushing's disease.

Authors:  Stephan Petersenn; Maria Fleseriu
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

Review 4.  Mifepristone: is there a place in the treatment of Cushing's disease?

Authors:  John D Carmichael; Maria Fleseriu
Journal:  Endocrine       Date:  2012-11-29       Impact factor: 3.633

Review 5.  Medical management of Cushing's disease: what is the future?

Authors:  Maria Fleseriu; Stephan Petersenn
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.